Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore reached its target enrollment of 540 patients in the TEBE-AM registrational Phase 3 trial (NCT05549297), which tests KIMMTRAK (tebentafusp) in previously treated advanced melanoma. The trial randomizes HLA-A*02:01-positive patients who progressed after prior therapy to tebentafusp monotherapy, tebentafusp plus pembrolizumab, or investigator's choice, with overall survival as the primary endpoint.
Key figures
- Drug Name
- KIMMTRAK (tebentafusp)
- Phase Of Trial
- Phase 3
- Trial id
- NCT05549297
- Primary endpoint
- overall survival
- Target enrollment
- 540
- Topline data timing
- as early as end of 2026
- Addressable patients
- 4000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.